November 13, 2017

Biolog granted patent on novel treatment for Clostridium difficile infection – seeks commercial partner

Hayward, CA – November 13, 2017 – Biolog, Inc. announced today that it has been granted US Patent 9,662,372 describing a new potential approach for treating life-threatening infections by the colon residing bacterium, Clostridium difficile (recently renamed as Peptoclostridium difficile). The patent describes the discovery by Biolog scientists that cationic compounds can rapidly inactivate the toxin produced by this...
Read More

About Us

Biolog is a world leader in cell-based phenotypic testing technologies and assays. We have focused our efforts on developing technologies and products to test properties of cells (phenotypes) very simply and efficiently.